NASDAQ:DFFN - Diffusion Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.39 -0.01 (-2.50 %)
(As of 08/20/2018 04:00 PM ET)
Previous Close$0.40
Today's Range$0.38 - $0.41
52-Week Range$0.31 - $2.97
Volume64,300 shs
Average Volume495,711 shs
Market Capitalization$17.68 million
P/E Ratio-0.35
Dividend YieldN/A
Beta-1.37
Diffusion Pharmaceuticals logoDiffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. was founded in 2001 and is headquartered in Charlottesville, Virginia.

Receive DFFN News and Ratings via Email

Sign-up to receive the latest news and ratings for DFFN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DFFN
CUSIPN/A
Phone434-220-0718

Debt

Debt-to-Equity RatioN/A
Current Ratio12.03
Quick Ratio12.04

Price-To-Earnings

Trailing P/E Ratio-0.35
Forward P/E Ratio-0.89
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash Flow$0.1970 per share
Price / Cash1.98
Book Value$0.42 per share
Price / Book0.93

Profitability

EPS (Most Recent Fiscal Year)($1.14)
Net Income$-1,360,000.00
Net MarginsN/A
Return on Equity106.29%
Return on Assets51.04%

Miscellaneous

Employees11
Outstanding Shares50,570,000
Market Cap$17.68 million

Diffusion Pharmaceuticals (NASDAQ:DFFN) Frequently Asked Questions

What is Diffusion Pharmaceuticals' stock symbol?

Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN."

How were Diffusion Pharmaceuticals' earnings last quarter?

Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) announced its earnings results on Monday, August, 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. View Diffusion Pharmaceuticals' Earnings History.

When is Diffusion Pharmaceuticals' next earnings date?

Diffusion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 12th 2018. View Earnings Estimates for Diffusion Pharmaceuticals.

What price target have analysts set for DFFN?

1 brokers have issued 1-year price objectives for Diffusion Pharmaceuticals' stock. Their forecasts range from $1.25 to $1.25. On average, they anticipate Diffusion Pharmaceuticals' share price to reach $1.25 in the next year. This suggests a possible upside of 220.5% from the stock's current price. View Analyst Price Targets for Diffusion Pharmaceuticals.

What is the consensus analysts' recommendation for Diffusion Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Diffusion Pharmaceuticals.

Who are some of Diffusion Pharmaceuticals' key competitors?

Who are Diffusion Pharmaceuticals' key executives?

Diffusion Pharmaceuticals' management team includes the folowing people:
  • Mr. David G. Kalergis, Co-Founder, CEO & Chairman (Age 69)
  • Dr. John L. Gainer, Co-Founder, Chief Scientific Officer & Director (Age 79)
  • Mr. Ben L. Shealy, Sr. VP of Fin., Treasurer & Sec. (Age 59)
  • Mr. Thomas E. Byrne, Gen. Counsel (Age 61)
  • Dr. David Randolph Jones M.D., Chief Medical Officer (Age 55)

Has Diffusion Pharmaceuticals been receiving favorable news coverage?

Press coverage about DFFN stock has trended somewhat negative this week, Accern reports. The research firm rates the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Diffusion Pharmaceuticals earned a news impact score of -0.15 on Accern's scale. They also gave media headlines about the company an impact score of 41.11 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Diffusion Pharmaceuticals.

How do I buy shares of Diffusion Pharmaceuticals?

Shares of DFFN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Diffusion Pharmaceuticals' stock price today?

One share of DFFN stock can currently be purchased for approximately $0.39.

How big of a company is Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals has a market capitalization of $17.68 million. The company earns $-1,360,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Diffusion Pharmaceuticals employs 11 workers across the globe.

How can I contact Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The company can be reached via phone at 434-220-0718 or via email at [email protected]


MarketBeat Community Rating for Diffusion Pharmaceuticals (NASDAQ DFFN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  73 (Vote Outperform)
Underperform Votes:  57 (Vote Underperform)
Total Votes:  130
MarketBeat's community ratings are surveys of what our community members think about Diffusion Pharmaceuticals and other stocks. Vote "Outperform" if you believe DFFN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DFFN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel